Operates two distinct businesses — real estate development and manufacture of active pharmaceutical ingredients (APIs). The Real Estate segment contributed 80.6% of FY26 segment revenue at ₹193.40 crore with an EBIT margin of 42.0%, while the API segment contributed 19.4% at ₹46.59 crore with a 12.1% EBIT margin. Standalone cost structure is dominated by other operating expenses at 39.9% of revenue and employee costs at 15.6%, while raw materials account for just 5.8% and depreciation 5.2%. Capex for the year was ₹38.25 crore (15.9% of revenue). Consolidated profits are heavily supplemented by the company's share of profits from associate Alembic Pharmaceuticals Limited, which contributed ₹19,145 lakh in FY26. Statutory auditors flagged a disputed electricity duty matter with a principal provision of ₹2,052.13 lakh and ₹3,500 lakh deposited with the Supreme Court. The Board has recommended a dividend of ₹2.40 per share (120% on face value) for FY26, unchanged from the prior year. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Real Estate Business (81%), Active Pharmaceutical Ingredients Business (19%). Diversified group with a real-estate-led top line, a smaller API manufacturing business, and consolidated earnings heavily lifted by an associate stake in Alembic Pharmaceuticals.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 78 | 127 | 157 | 222 | 240 |
| EBITDA (ex other income) | 14 | 30 | 57 | 94 | 90 |
| margin % | 17.8 | 23.4 | 36.1 | 42.2 | 37.7 |
| Owners' profit | 222 | 191 | 269 | 311 | 230 |
| EPS, as reported (₹) | 8.65 | 7.43 | 10.46 | 12.10 | 12.36 |
| ROE % · ROCE % | 8.9 · 3.8 | 9.2 · 4.1 | 12.3 · 4.6 | 13.3 · 6.6 | 13.0 · 6.1 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Cash from operations | (18) | 39 | 23 | 86 | 120 |
| Capex | (1) | (0) | (1) | (7) | (38) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 53 | 58 | 60 | 50 | 56 | 74 | 60 | 49 |
| Profit before tax | 82 | 27 | 27 | 20 | 85 | 26 | 18 | 17 |
| Net profit | 121 | 65 | 68 | 62 | 128 | 60 | 67 | 65 |
| EPS (₹) | 4.71 | 2.55 | 2.67 | 2.40 | 5.00 | 2.34 | 2.61 | 2.53 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Active Pharmaceutical Ingredients Business | 47 | 19.4 |
| Real Estate Business | 193 | 80.6 |
| Total, before eliminations | 240 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DLF LIMITED | 1,59,533 | 35.9 | 3.51 | 48.1 | 9.7 | 6.0 | 8.6 | 37.1 |
| LODHA DEVELOPERS LIMITED | 1,11,589 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 12 Aug 2026 · Alembic Limited Q1 FY27 results published in newspapers | compliance | minimal | — | — |
| 11 Aug 2026 · AGM voting results: all 5 resolutions approved, 98.8% to 100% in favour | compliance | minimal | — | — |
| 11 Aug 2026 · Alembic 119th AGM voting results: all 5 resolutions passed | board shareholder meetings | low | — | — |
| 11 Aug 2026 · Alembic Limited 119th AGM held on 11 Aug 2026; 5 resolutions tabled | board shareholder meetings | medium | — | — |
| 11 Aug 2026 · Alembic notifies special window for physical share dematerialisation | compliance | minimal | — | — |
| 11 Aug 2026 · Q1 FY27 results: Consolidated PAT at Rs 64.89 cr, standalone at Rs 14.68 cr | results | high | — | — |
| 11 Aug 2026 · Alembic Q1FY27: PAT slips, associate share lifts consolidated profit | results | high | — | — |
| 31 Jul 2026 · Board meeting on 11 Aug 2026 to approve Q1 FY27 results | results | low | — | — |
| 13 Jul 2026 · Please find enclosed herewith a specimen copy of the letter sent to the shareholders of the Company whose email address are not registered with the Company / Depositories providing them .... | compliance | minimal | — | — |
| 11 Jul 2026 · 119th AGM on 11 Aug 2026; Record Date 4 Aug for FY26 Dividend | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|
| 27.0 |
| 4.76 |
| 22.1 |
| 14.6 |
| 15.7 |
| 25.1 |
| 40.5 |
| THE PHOENIX MILLS LTD | 67,594 | 52.8 | 4.73 | 26.2 | 10.9 | 9.9 | 32.7 | 63.4 |
| PRESTIGE ESTATE LTD | 64,519 | 56.6 | 3.85 | 18.5 | 7.8 | 6.8 | 11.8 | 38.1 |
| OBEROI REALTY LIMITED | 63,306 | 20.8 | 3.53 | 18.2 | 14.0 | 15.5 | 24.0 | 61.1 |
| GODREJ PROPERTIES LTD | 52,653 | 32.9 | 2.72 | 23.7 | 9.5 | 11.4 | 46.3 | 107.7 |
| ANANT RAJ LIMITED | 21,490 | 36.2 | 3.69 | 29.3 | 9.6 | 10.2 | 58.7 | 32.1 |
| BRIGADE ENTER. LTD | 20,941 | 24.4 | 2.78 | 15.7 | 9.6 | 6.8 | 23.9 | 41.9 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 8.4 | 21.8 | 6 of 57 | 91% |
| P/B | 1.1 | 2.1 | 18 of 64 | 73% |
| ROCE | 6.0 | 6.8 | 35 of 67 | 49% |
| ROE | 13.0 | 8.2 | 17 of 67 | 76% |
| Debt / Equity | 0.0 | 0.4 | 11 of 67 | 85% |
| EBITDA margin | 44.0 | 29.6 | 13 of 66 | 82% |
| Revenue growth | (2.0) | 12.8 | 48 of 67 | 29% |
| Profit growth | 5.3 | 7.5 | 35 of 66 | 48% |
| Market cap | 2704 | 2250 | 30 of 67 | 56% |
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
